A Phase 4 interventional study of Electronic Health Record Review and Fentanyl in Head and Neck Carcinoma, Hypopharyngeal Carcinoma and Laryngeal Carcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by OHSU Knight Cancer Institute · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Hypopharyngeal Neoplasms with a site in United States — 24 open to participants now, 32 under way, 3 of them phase 3. Hypopharyngeal Neoplasms · United States.
Among the 86 studies in Hypopharyngeal Neoplasms with a site in United States, this one is the 29th largest by planned enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 4, reaches primary completion later than 25 of the 31 other live ones, and was the 84th registered.
148 studies on the registry are indexed under Hypopharyngeal Neoplasms; 45 are open to participants now.
Browse Hypopharyngeal Neoplasms studies →24 of the 86 studies in Hypopharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Metaclipse Therapeutics Corporation · Sites in United States
Ages 18+
Emory University · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Hypopharyngeal Neoplasms studies recruiting now, 23 (61%) set no upper age limit and 8 (21%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 36 · Phase 3 7 · Phase 4 3
First in 1995; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is close to the median of 59 across 110 interventional studies indexed under Hypopharyngeal Neoplasms.
Median enrollment 45 across the 69 interventional studies, 586 across the 8 observational. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 86 have an industry lead sponsor. The 10 most frequent:
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
OHSU Knight Cancer Institute has 1 study filed under Hypopharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypopharyngeal Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01473784Ohio State University Comprehensive Cancer CenterTransoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck | 2026-12-31 |
| NCT05337631University Hospital FreiburgSpecial Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
| NCT06532279NRG OncologyTesting the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | 2027-01-01 |
| NCT02253238M.D. Anderson Cancer CenterSensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | 2027-04-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 86 studies in Hypopharyngeal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase IV trial compares how well methadone plus standard fentanyl given during surgery (intraoperative) works compared to intraoperative standard fentanyl alone in managing pain after surgery (postoperative) among patients with head and neck cancers. For most head and neck cancers, the standard treatment is surgery to remove the cancer followed by surgical reconstruction, which often requires tissue harvested from another part of the body-known as a "free flap tissue transfer". These procedures are highly complex, demand a two-surgeon team, and often take many hours to complete. The combination of multiple operative sites and extent of the surgery contributes to significant postoperative pain. Methadone is not yet used in the head and neck population but has been utilized in other subspecialties like spine and cardiac surgery. The benefits of methadone may include improved pain control in the first 72 hours postoperatively requiring less opioids postoperatively and improvement in overall pain scores. Giving intraoperative methadone plus standard fentanyl may work better than fentanyl alone in managing postoperative pain among patients with head and neck cancers.
PRIMARY OBJECTIVE:
I. To assess the effectiveness of intraoperative methadone compared to control in reducing the requirements of morphine milliequivalents (MMEs).
SECONDARY OBJECTIVES:
I. To assess the effectiveness of intraoperative methadone compared to control in reducing objective measures of pain, including MMEs, for up to 72 hours postoperatively.
II. To assess how soon after surgery patients require additional opioid administration for those in the methadone group compared to control.
III. To assess whether additional pain management is required less frequently in the methadone group compared to control.
EXPLORATORY OBJECTIVES:
I. To assess if there is an increase in the incidence of post-operative emesis events in the methadone group compared to the control.
II. To assess the effectiveness of intraoperative methadone compared to control on patient's pain scores daily.
III. To assess whether there is a difference in respiratory status between the methadone group compared to the control.
IV. To assess whether higher rates of naloxone administration are required in the methadone group.
V. To assess if pain control impacted acute recovery more effectively in the methadone group compared to control.
VI. Clinical outcomes that are standard of care may be assessed. VII. To assess if there is any impact on pain at \~1 month postoperatively compared to the control group.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive methadone intravenously (IV) at the time of incision during standard of care (SOC) surgery. Patients also receive SOC fentanyl prior to SOC laryngoscopy procedure.
ARM II: Patients receive SOC fentanyl prior to SOC laryngoscopy procedure and surgery.
After completion of study intervention, patients are followed up at 4-6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with proven head and neck cancer*. Diagnosis will be confirmed by Otolaryngology-Head and Neck Surgery (OTOHNS) team at our center
Undergoing surgical intervention with ablative and/or reconstructive OTOHNS surgeons for one of the following:
Resections with pedicled flaps (e.g., pectoralis major, latissimus) with an expected case time of > 4 hours
Exclusion Criteria:
Positive screening at interview for illicit drug use, not including marijuana
Currently on CYP therapies noted in the Food and Drug Administration (FDA) methadone pamphlet to have either decreased efficacy of therapy or reduced metabolism of methadone with concurrent use
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive methadone IV at the time of incision during SOC surgery. Patients also receive SOC fentanyl prior to SOC laryngoscopy procedure.
Other: Electronic Health Record Review · Drug: Fentanyl · Device: Laryngoscopy · Drug: Methadone · Procedure: Surgical Procedure · Other: Survey Administration
Patients receive SOC fentanyl prior to SOC laryngoscopy procedure and surgery.
Other: Electronic Health Record Review · Drug: Fentanyl · Device: Laryngoscopy · Procedure: Surgical Procedure · Other: Survey Administration
Ancillary studies
Given SOC fentanyl
Also known as: Abstral, Duragesic
Undergo SOC laryngoscopy
Given IV
Undergo SOC surgery
Also known as: Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
Ancillary studies
Total morphine milligram equivalents (MMEs) administered in the first 24 hours postoperatively
MMEs will be calculated using the Stanford Opioid Equivalent calculator and data is obtained from the medication administration record (MAR) in epic. Out of room is standard terminology for when the patient leaves the operating room and a required timestamp per standard workflows across all institutions. Two-sided two-sample t-test will be used to compare mean MMEs administered in the first 24 hours between the methadone and control groups. If data is right skewed, log transformation will be performed prior to t-test. If severe violation to normality assumption is detected graphically or by Shapiro-Wilk hypothesis test, Wilcoxon rank-sum test will be performed instead.
Time frame: From out of room to 24 hours postoperatively
Cumulative MMEs between 24-48 hours postoperatively and 48-72 hours postoperatively
Will be analyzed as the same approaches as the primary endpoint with two-sided two-sample t-test. If data is right skewed, log transformation will be performed prior to t-test. If severe violation to normality assumption is detected graphically or by Shapiro-Wilk hypothesis test, Wilcoxon rank-sum test will be performed instead.
Time frame: From 24 hours postoperatively to 72 hours postoperatively
Time to first dose of oral opioid administered & intravenous opioid administered
Will be assessed using a time-to-event analysis (log-rank test) to compare between the two groups.
Time frame: From out of room to discharge, an average of 5 days
Acute pain service (APS) consult placement (Yes/No) and outcome of that consult
Chi-squared test (or Fisher's exact test if any expected count is \< 5) will be used to compare proportion of APS placement between the two groups. Chi-squared test (or Fisher's exact test if any expected count is \< 5) will be used to assess the ambulatory goals comparing the proportion of goals achieved between the two groups on each post-operative day (POD) period. (POD0, POD1 and POD2).
Time frame: From out of room to discharge, an average of 5 days
Started Sep 2026 (actual). Primary completion is estimated for Jul 2029, 34 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone
OHSU Knight Cancer Institute →